Skip to main content
. 2024 Nov 29;20:799–809. doi: 10.2147/TCRM.S481128

Figure 3.

Figure 3

(A) Case (A) Extensive maculopapular rash present on the back. (B) Case (B) Extensive maculopapular rash on the lower extremities. (C) Pink stripes on the legs of Case C following two months of medication use. (D) Transparent lines appeared on the right leg of Case C several months after reducing the dosage. (E) Transparent lines appeared on the left leg of Case C several months after decreasing the dosage.